For an adult who suspects they have ADHD, the path to a diagnosis in the United States usually begins with a phone call that ends in a waitlist. Specialist psychiatrists are scarce, primary care visits rarely include the structured assessment that a formal evaluation requires, and coaching, the part many patients say helps most day to day, sits outside what insurance typically covers. Agave Health, a New York-based virtual clinic founded in 2022, is trying to collapse that fragmented journey into a single membership.
The company sells one plan that includes a clinical survey, therapist analysis, two 45-minute synchronous virtual sessions with a therapist, and a 30-minute session that delivers the evaluation outcome and a recommended treatment path [Agave Health]. From there, members can continue with ongoing therapy and ADHD coaching inside the same product, with cancel-anytime billing [Agave Health]. The company describes itself as "a virtual clinic providing holistic care for adults with ADHD" [Agave Health], and its public materials make a point of pairing clinical care with the executive-function coaching that patient communities consistently ask for.
The bet
Agave's wager is that adult ADHD is a category large enough, and underserved enough, to support a dedicated virtual clinic rather than a feature inside a general mental-health app. The patient population is specific: adults, often diagnosed late or not at all, whose symptoms show up as missed deadlines, emotional dysregulation, and the working-memory lapses the company writes about in its own clinical content [Agave Health]. The product wedge is the bundle. Instead of asking a member to find a prescriber in one place, a therapist in another, and a coach in a third, Agave packages diagnosis, therapy, and coaching under one subscription, with an option for employers to sponsor coverage through a company code [Agave Health].
Standard of care today for adult ADHD in the U.S. typically runs through a primary care physician referral to a psychiatrist or psychologist for evaluation, followed by a stimulant or non-stimulant medication trial managed by the prescriber, with therapy and coaching layered on separately if the patient can find and afford them. Wait times for adult psychiatric evaluation can stretch for months in many metro areas, and the recent federal scrutiny of telehealth ADHD prescribing, including DEA rule-making around controlled substances, has made the medication pathway more complicated for virtual-first providers. Agave's public materials emphasize therapy and coaching rather than prescribing, which is a meaningful design choice in the current regulatory climate.
Why it could be big
The tailwinds are real. Adult ADHD diagnosis rates have risen sharply over the past decade, employer interest in neurodivergent-friendly benefits has grown, and the post-pandemic acceptance of virtual behavioral care has held up better than virtual care in many other specialties. Agave is backed by Good Company and SeedIL Ventures, with Good Company also listed as an accelerator relationship [Tracxn, 2025]. Good Company's portfolio focus on consumer health and SeedIL's early-stage Israeli network give the company two distinct bench strengths: U.S. consumer health distribution and the Tel Aviv engineering and clinical-product talent pool that several digital-health exits have come out of in recent years.
The credible upside, if execution holds, is a defensible adult-ADHD brand that can sell both direct to consumers and through employer benefits channels. The employer angle is already live: Agave's site invites companies to sponsor subscriptions and provides a code-based access flow [Agave Health]. That dual motion, consumer acquisition that doubles as a proof point for HR buyers, is the same playbook that helped earlier digital-health categories like fertility and musculoskeletal care reach scale.
The team
Agave was co-founded by Eve Lise Mamane and Ori Fruhauf [Tracxn, 2025]. Mamane has spoken publicly about the founder experience, including in a Calcalist interview on women building companies in tech [Ctech]. The clinical bench is anchored by Dr. Singh, who advises Agave on clinical product and previously served as Chief Behavioral Science Officer at Dario Health (NASDAQ: DRIO) following Dario's acquisition of her prior company wayForward, an enterprise mental-health SaaS business that sold into employers and health plans [Agave Health]. Dr. Singh also holds an adjunct faculty position at Columbia University in the Division of Molecular Imaging and Neuropathology, Department of Psychiatry [Agave Health]. That background, an enterprise behavioral-health exit plus an academic psychiatry affiliation, maps closely to the two channels Agave is trying to build into.
What the bears say
The most credible concern is competitive pressure on the adult-ADHD category specifically. The space attracted a wave of well-funded virtual-first entrants during the pandemic, several of which leaned heavily on stimulant prescribing and then faced regulatory and payer headwinds. A new entrant has to differentiate on something other than speed-to-prescription. Bulls would answer that this is precisely Agave's design: the membership leads with assessment, therapy, and coaching rather than a medication funnel [Agave Health], which is both a clinically defensible posture and a more durable one if DEA telehealth rules tighten further. Whether that positioning converts at consumer-acquisition costs that work for a seed-stage company is the open question, and it is the one the next 12 months should answer.
What to watch
The milestones to track are concrete. First, any disclosed Series A round, which would signal that Agave's early membership cohort is retaining at rates investors find credible for a subscription behavioral-health product. Second, named employer customers, the proof point that the sponsor-code flow is converting HR buyers and not just sitting on the site. Third, any peer-reviewed or registry data on member outcomes, which would move Agave from a well-designed consumer product into a clinically validated one and would matter to both health-plan contracting and to the academic credibility Dr. Singh's involvement implies. For a patient population that has spent years being told to try harder, a clinic built specifically around how adult ADHD actually shows up is a thesis worth watching.